218 related articles for article (PubMed ID: 38172228)
21. Deep learning-radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients.
Kim S; Lim JH; Kim CH; Roh J; You S; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Heo J
Sci Rep; 2024 Jan; 14(1):922. PubMed ID: 38195717
[TBL] [Abstract][Full Text] [Related]
22. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
23. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
[TBL] [Abstract][Full Text] [Related]
26. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
28. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
30. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
31. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
32. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
[No Abstract] [Full Text] [Related]
33. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
34. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
35. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
36. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.
Le NQK; Kha QH; Nguyen VH; Chen YC; Cheng SJ; Chen CY
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502160
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
38. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
[TBL] [Abstract][Full Text] [Related]
39. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
[TBL] [Abstract][Full Text] [Related]
40. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
